A different approach to primary biliary cholangitis (PBC) treatment

IQIRVO is thought to act on multiple targets in the liver. Two of these targets are PPAR alpha and PPAR delta.a 
In the liver, PPAR alpha and PPAR delta help control:

Liver icon showing liver inflammation and toxic substances in the liver Liver icon showing liver inflammation and toxic substances in the liver

a This information is based on animal studies, and the way IQIRVO works is not fully understood.

PPAR=peroxisome proliferator-activated receptor.

Expect more from your PBC treatment

If you need more from your PBC treatment, adding IQIRVO can help.

IQIRVO was studied in a 52-week clinical trial of 161 people with PBC.
  • 102 people took IQIRVO in addition to ursodiolb, and 6 people who were intolerant to ursodiol took IQIRVO alone
  • The results were compared with 53 people who took ursodiol alone

Treatment goals in the trial were defined as:

  • Lowering alkaline phosphatase (ALP) to less than 1.67 times the upper limit of normalc
  • Decreasing ALP by at least 15%
  • Maintaining normal bilirubin

13x more 
people with PBC

met the established treatment goals when taking IQIRVO

compared to people who took ursodiol alone.d

d 51% of people taking IQIRVO met the treatment goals compared to 4% of people who took ursodiol alone.

In the clinical trial:

ALP lowered icon with a blue stained glass circle featuring a down arrow

IQIRVO lowered ALP in as quickly as 4 weeks, and the effects were sustained over 52 weeks.

ALP normalized icon with a yellow stained glass circle featuring a check mark

By 52 weeks, some people taking IQIRVO (15%) achieved a normal ALP level, compared to no one who took ursodiol alone.

IQIRVO can lower and even normalize ALP.

Person itching

Itch-related results

IQIRVO was studied in people who had moderate-to-severe levels of itch defined as a PBC Worst Itch Numeric Rating Scale (WI-NRS) score greater than or equal to 4.

People taking IQIRVO reported an average reduction of 1.93 points in the WI-NRS score, compared to people taking ursodiol alone (average reduction of 1.15 points).

When asked questions from the itch section of the PBC-40 questionnaire and the 5-D itch scale:

People taking IQIRVO reported an average reduction of 2.5 points in the PBC-40 itch score, compared to people taking ursodiol alone (average reduction of 0.1 points).

Ampersand with lines above and below

People taking IQIRVO reported an average reduction of 4.2 points in the 5-D itch total score, compared to people taking ursodiol alone (average reduction of 1.2 points).

Itch was a secondary outcome of the study and results did not reach statistical significance. Data should be reviewed with caution. If you have questions about this limitation, your doctor can help explain it further.

After the trial was over,

97% of people taking IQIRVO

chose to continue taking IQIRVO in an ongoing follow-up study.

Ask your doctor if IQIRVO may be right for you

Monitoring markers of PBC progression, like ALP and bilirubin, is key to an effective PBC treatment plan. Use the IQIRVO Discussion Guide to help you talk about your treatment with your doctor.

Download the Discussion Guide

Safety and tolerability

The most common side effects reported in the clinical trial were:

ursodiol alone

Weight gain

23% vs 21%


11% vs 9%

Abdominal pain

11% vs 6%


11% vs 6%


11% vs 2%


8% vs 4%


8% vs 2%

Muscle pain

7% vs 2%


6% vs 0%

Gastroesophageal reflux disease

6% vs 2%

Dry mouth

5% vs 2%

Weight loss

5% vs 0%


5% vs 4%

Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Pill icon

Once-daily dosing

IQIRVO is an 80-mg pill taken orally. IQIRVO can be taken with or without food.

b Ursodeoxycholic acid, or ursodiol, may also be referred to as UDCA.

c The upper limit of normal, or ULN, is the high end of a normal range for a lab value. When assessing a person’s response to treatment for PBC, the definition of response may include an ALP level in relation to the ULN (for example, an ALP level of 1.67 x ULN).

Indication and Important Safety Information

What is IQIRVO® used for?

IQIRVO is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well to UDCA, or used alone in patients unable to tolerate UDCA.

IQIRVO is not recommended for use in people who have symptoms or signs of advanced liver disease. It is not known if taking IQIRVO will improve your chance of survival or prevent liver decompensation.

It is not known if IQIRVO is safe and effective in children under 18 years of age.

What Warnings should I know about IQIRVO?

  • IQIRVO can cause muscle problems (myalgia, myopathy, rhabdomyolysis) and muscle pain that can be severe. Treatment with IQIRVO may cause muscle pain or worsen existing pain and can increase the level of an enzyme in your blood called creatine phosphokinase (CPK); both can be a sign of muscle damage. If there is new or worsening muscle pain, your healthcare provider may examine you and perform a blood test. Stop taking IQIRVO and call your healthcare provider right away if you have any of the following signs or symptoms: severe muscle pain, unexplained soreness, unexplained muscle weakness, or dark, reddish urine.
  • IQIRVO may increase the risk of bone fractures. Tell your healthcare provider about any bone fractures, or if you develop pain, or have changes in your ability to move around.
  • IQIRVO may cause harm to an unborn baby when taken during pregnancy. Women taking IQIRVO who can become pregnant should use effective birth control during treatment and for 3 weeks after the last dose of IQIRVO. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you may be pregnant.
  • IQIRVO can cause liver problems and abnormal liver blood test results. Your healthcare provider should do tests before starting and during treatment with IQIRVO to check your liver function. Tell your healthcare provider right away if you experience any of the following during treatment with IQIRVO: swelling of your stomach-area (abdomen), yellowing of your skin or whites of your eyes, black, tarry, or bloody stools, mental changes such as confusion, being sleepier than usual or harder to wake up, slurred speech, mood swings, or changes in personality, or coughing up or vomiting blood, or your vomit looks like coffee grounds. If you have severe stomach-area (abdomen) pain, nausea, vomiting, diarrhea, loss of appetite or weight loss, new or worsening fatigue, weakness, fever and chills, light-headedness, or less frequent urination, tell your healthcare provider right away.
  • Some people taking IQIRVO had allergic reactions, which may include rash, trouble breathing, itching, or swelling of your face, lips, tongue, or throat. If you experience any of these, stop taking IQIRVO, call your healthcare provider right away or go to the nearest hospital emergency room.
  • IQIRVO can cause blockage of the bile duct and may increase your risk of gallstones. Call your healthcare provider right away if you develop pain in the upper right stomach area or yellowing of the skin.

You should not use IQIRVO if you:

  • Have advanced liver disease.
  • Are pregnant or plan to become pregnant. IQIRVO can harm your unborn baby. You should not become pregnant during treatment with IQIRVO.
  • Are breastfeeding or plan to breastfeed. It is not known if IQIRVO passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby if you take IQIRVO.

What are the side effects of IQIRVO?

The most common side effects of IQIRVO include weight gain, diarrhea, stomach pain, nausea, vomiting, joint pain, constipation, muscle pain, bone fractures, gastroesophageal reflux disease (GERD), dry mouth, weight loss, and rash. These are not all of the possible side effects of IQIRVO. Call your doctor for medical advice about side effects.

What other medications might interact with IQIRVO?

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. IQIRVO can affect the way certain medicines work. Certain medicines may affect the way IQIRVO works. If you take a bile acid binding resin, take IQIRVO at least 4 hours before or after you take your bile acid resin.

You are encouraged to report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. You may also report side effects to Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127.

Please see full Prescribing Information.